Harvard Apparatus Regenerative Technology (NASDAQ: HRGN) is a regenerative medicine development-stage company focused on bioengineered organ implants, with a secondary business selling dietary supplements through its Hong Kong subsidiary, Consumer Health Products. Revenue is generated from product sales of dietary supplements, as the company's core regenerative medicine product candidates, including an esophageal implant granted FDA Orphan Drug Designation in November 2016, have not yet received regulatory approval anywhere in the world. HRGN contracted IQVIA as its CRO to manage its first clinical trial, which activated its first site and began screening patients in Q3 2023, but has experienced delays in patient recruitment due to comorbid conditions among participants, stringent FDA eligibility criteria, and logistical challenges across trial sites. The company operates at a net loss, carries going concern risk, and disclosed in its 10-K filed March 19, 2026 that it may be forced to curtail or cease operations if it does not raise additional capital before or during Q2 2026.

Revenue model

Transactional product revenue from dietary supplement sales through Consumer Health Products, a Hong Kong subsidiary. No revenue from regenerative medicine product candidates, which remain in clinical development and lack regulatory approval as of the 10-K filed March 19, 2026.

Products and services

Bioengineered esophageal implant in clinical-stage development (FDA Orphan Drug Designation granted November 2016). Dietary supplements sold through Consumer Health Products subsidiary in Hong Kong.

Customers and end markets

Consumer health products customers for dietary supplements. Target end market for regenerative medicine is patients requiring esophageal reconstruction following cancer, injury, or congenital abnormalities, a rare disease population under the Orphan Drug Act threshold of fewer than 200,000 U.S. persons.

Geographic exposure

United States (clinical trials, regulatory engagement with FDA). Hong Kong (Consumer Health Products subsidiary). Regulatory filings also reference the European Union and China as intended future markets.

Competitors

Pharmaceutical companies developing regenerative medicine treatments, Biotechnology companies developing bioengineered or regenerative organ technologies, Medical device companies in regenerative medicine, Academic and clinical centers developing bioengineered organ technologies

Source: SEC 10-K, filed 2026-03-19

Industry: Surgical & Medical Instruments & Apparatus Peers: Mink Therapeutics Inc Black Diamond Therapeutics Inc Apexigen, Inc. Genprex Inc iBio Inc Passage Bio Inc Spero Therapeutics Inc Taysha Gene Therapies Inc